We met up with Dr Jonathan Talamo at ESCRS 2018 to learn about Johnson & Johnson’s new developments in eye care. Dr Talamo revealed that around 50% of the world’s population require some form of eye care; however, only around 10% of those receive it. In this vein, Johnson & Johnson hope to become the world’s leading eye care company and address some of these figures. One of the most common ophthalmic disorders is dry eye, and there is yet to be a standardised global treatment paradigm. Johnson & Johnson have developed LipiScan® and LipiView® for the diagnosis of meibomian gland disease—the contributing factor to dry eye—and LipiFlow® for meibomian gland treatment. In the field of intraocular lenses (IOLs), Johnson & Johnson have launched the TECNIS Symfony® extended depth of focus IOL which addresses presbyopia and astigmatism while providing a full range of vision.
The latest from Johnson & Johnson Vision at ESCRS 2018, Vienna, Austria. (0:05)
Speaker disclosures: Jonathan Talamo is an employee of Johnson & Johnson.
Filmed at the 36th Congress of the European Society of Cataract & Refractive Surgeons (ESCRS), Vienna, Austria, 22–26 September 2018.